Home › Chronic Kidney Disease › NCT06906627

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Recruiting

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Screening Program-

Inclusion Criteria:

* Adults with type 2 diabetes (T2D)
* Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).
* Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR

Exclusion Criteria:

• Chronic kidney disease (CKD) diagnosis

About the study

IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.

What is being tested

(IRIS-CKD Screening Program): Home Kit (other)
(IRIS-CKD Screening Program): Standard Lab Order (other)

Sponsor: Duke University · Participants: 750 · Started: Oct 28, 2025

Contact the study team

Gretchen Sanders, MSN · Phone: 919 6687829

Official record on ClinicalTrials.gov — NCT06906627

Locations in the U.S.

Alabama	University of Alabama, Birmingham
Florida	Orlando Health, St. Petersburg
Michigan	University of Michigan, Ann Arbor
Minnesota	Essentia Health, Duluth
North Carolina	Duke University, Durham Houston Methodist, Houston
Texas	Baylor Scott & White, Temple

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.